Screening and the HPV vaccine have led to drops in cervical cancers over the last two decades in the U.S., a new study finds, but the gains are offset by a rise in other tumors caused by the virus.
“A common misperception is the HPV vaccine has solved the problem of HPV-associated cancers. Unfortunately, that couldn’t be further from the truth,” said Dr. Maura Gillison of the University of Texas MD Anderson Cancer Center, who was not involved in the study.
Results were released Wednesday by the American Society of Clinical Oncology ahead of presentation at its annual meeting next month.
HPV, or human papillomavirus, is the nation’s most common sexually spread infection. Most HPV infections cause no symptoms and go away without treatment.
But some cause genital warts and others develop into cancers, about 35,900 each year, according to the Centers for Disease Control and Prevention.
In the U.S., the HPV vaccine has been recommended since 2006 for girls at age 11 or 12, and since 2011 for boys the same age, and catch-up shots are recommended for anyone through age 26 who hasn’t been vaccinated. Experts agree it will take years to see the true impact because it can take decades for a chronic HPV infection to turn into cancer.
What’s driving the HPV cancer trends is the youthful sexual behavior of baby boomers before the vaccine was out. The vaccine works best when given at younger ages before people are exposed to HPV through sexual activity, so it arrived too late for the boomers.
“Sexual trends began changing and liberalizing in the late ’60s, and continued into the ’70s and ’80s, until the HIV epidemic” caused people to be more cautious, said Dr. Ernest Hawk, cancer prevention specialist at MD Anderson, who was not involved in the study.
“People had many more partners and many more types of interactions,” Hawk said.
Researchers from the U.S. and Taiwan looked at U.S. cancer statistics from 2001-2017, finding more than 657,000 cases of HPV-related cancers, 60% in women and 40% in men. While cervical cancer cases fell by about 1% per year, other types rose.
For men, oral and throat cancers increased the most, at nearly 3% a year. For women, anal cancer and a rare rectal cancer increased the most, also nearly 3% annually.
The biggest drop in cervical cancers was seen in young women who would have been the first to get the HPV vaccine when they were preteens, said lead author Dr. Cheng-I Liao of Kaohsiung Veterans General Hospital in Taiwan.
That suggests the vaccine played a role, along with Pap tests, which have been driving down cervical cancer cases for decades.
No screening tests exist for the other cancers, although research is underway.
One vaccine, Merck’s Gardasil 9, is available in the U.S. The cost is fully covered by private and public health insurance.
Human papillomavirus (HPV) infections account for over 600,000 new cancer cases every year [1]. HPV is implicated in approximately 70% of oropharyngeal cancers (OPCs), 90% of anal cancers, and virtually all cases of invasive cervical cancer (ICC) in the U.S [2]. HPV carcinogenesis is mediated by its E6 and E7 oncoproteins, which force differentiating epithelial cells to re-enter the cell cycle to grow and increase viral production [3].
Although most HPV infections resolve over time, persistent infection can cause catastrophic cell-cycle instability and eventually lead to invasive cancer [2]. Nevertheless, HPV presence alone is insufficient for cancer formation. Factors unique to the individual mucosal sites such as epithelial surface integrity, mucosal secretions, immune regulation, and the local microbiota likely play a role in HPV persistence and progression to cancer [2–4]. Dysbiosis of the microbiome can have profound effects on overall health and has recently been linked to cancer progression and treatment responses [5].
Methodological advances in microbiome sequencing and analysis have enabled these recent sweeping advances in knowledge. In particular, 16S ribosomal RNA (rRNA) amplicon sequencing is frequently used. This cost-effective method sequences specific hypervariable regions of the 16S rRNA gene and clusters the identified bacteria into operational taxonomic units (OTUs) that can quantify diversity metrics and relative abundances, as well as provide genus-level identification [6]. However, 16S rRNA subregion sequencing has inherent disadvantages, including the inability to provide species-level identification and metagenomic functionality.
These deficiencies could be overcome with whole-genome shotgun (WGS) sequencing. WGS deciphers broad regions of entire microbial genomes with significantly more sequencing depth but at a greater cost and use of bioinformatics resources than 16S rRNA analysis [7].
Despite these barriers, notable advantages include enhanced species-level identification and accuracy, improved microbial diversity detection, insight into genome functionality and structure, and the ability to identify nonbacterial microorganisms such as viruses and fungi, which are also critical parts of a tissue’s microbiome [7]. Used in conjunction, these complementary methods may provide further clues to understanding the microbiome’s role in HPV carcinogenesis.
HPV cancers may be uniquely affected by the microbiome since these solid tumors arise in the mucosa of the orogenital tract, which each have unique and diverse microbiomes. Insights into the potential influence of the microbiome on viral persistence, immune response, host-mucosal environment, and cancer treatments for HPV-related cancers are just beginning to emerge. In this review, we will discuss how the microbiome may play a pivotal role in the formation of HPV-driven cancers.
Microbiome factors in cervical intraepithelial neoplasia
The role of the microbiome in HPV-driven diseases has been extensively studied in cervical intraepithelial neoplasia (CIN). Table 1 presents an overview of key CIN and CIN-related (CIN/ICC) microbiome studies. In 1992, one of the first studies characterizing CIN microbiota utilizing laboratory culture discovered the characteristic presence of “abnormal vaginal flora,” which future studies would later confirm through 16S rRNA analysis [8].
Through the generation of reproducible microbiome archetypes, or community-state types (CSTs), 16S sequencing allowed CIN studies to cross-compare findings [9]. The most common CSTs found in CIN patients were CSTs characterized by Lactobacillus depletion, anaerobic bacteria predominance, and Lactobacillus iners dominance. These CSTs were significantly associated with preinvasive disease, increased disease severity, and disease invasiveness.
Additionally, increased vaginal microbe diversity and richness were associated with increased rates of HPV infection and persistence, as well as higher CIN severity [10–13]. Sneathia was significantly enriched in CIN samples in multiple studies, and its presence was associated with changes in immune mediators [12,14]. But, similar to the majority of “enriched microbiota” found using 16S, its pathogenic or protective role is not well understood.
https://doi.org/10.1371/journal.ppat.1008524.t001
Lactobacillus species have been better studied and appear to serve primarily protective roles with some exceptions. L. crispatus dominance has been strongly associated with a healthy vaginal microbiome and is responsible for producing high quantities of lactic acid and secretion of protective proteins throughout mucosal microenvironment [15].
Conversely, L. iners is the most commonly reported Lactobacillus-dominated CST in CIN patients. L. iners produces low amounts of lactic acid with no reported host-protective peptide production. L. iners CSTs are also the most likely to transition to CSTs characteristic of CIN patients, possibly because of its ability to adapt to a variety of pH environments and its distinct lack of bacteriocin synthesis genes, all of which allow abnormal cervicovaginal bacteria to thrive [15,16].
An association between bacterial vaginosis (BV) and CIN has long been suggested [17]. CIN and BV present similar vaginal microbiomes characterized by decreased Lactobacilli abundance, increased predominance of abnormal anaerobic bacteria, and increased diversity [17]. Studies suggest a variety of mechanisms in which BV may result in HPV persistence and CIN. Decreased abundance of lactic-acid–producing Lactobacilli resulting in abnormally high vaginal pH (>4.5) can cause bacterial overgrowth and decreases in protective flora [14].
This disruption in the colonization of protective microbiota can result in weakened defense mechanisms to fend off viral infections. BV is also associated with increased production of epithelial-lining–degrading enzymes which can allow HPV infection to initiate [17]. Additionally, BV has been associated with increased levels of proinflammatory cytokines and chronic inflammation at mucosal sites [18]. Women with BV expressed increased levels of cytokine interleukin (IL)-1β and decreased levels of antiinflammatory molecule SLPI (secretory leukocyte protease inhibitor) [18].
Furthermore, toll-like receptors (TLRs) act as a first-line of defense in recognizing viral infection and foreign bacteria. TLR9 has been suggested to recognize HPV infections and initiate an immune response, while E6 and E7 oncoproteins directly down-regulate TLR9 at a transcriptional level [19]. BV incidence has been associated with SNPs in TLR2/7, but their exact roles in BV are not well understood [20]. All of these bacterial, mucosal, and immune complications related to BV can result in an increased susceptibility to HPV infection and the development of high-grade intraepithelial lesions.
Microbiome factors in ICC
HPV persistence is necessary but insufficient for the formation of ICC, and it is now believed the local microbiota may play a role in tumorigenesis. Table 1 provides a summary of ICC-related microbiome studies. One study utilized shotgun metagenomic sequencing to reveal potential metabolic and functional roles of the microbiome involved in inflammation and defense mechanism pathways but additional WGS studies are required to confirm these findings [21].
Additionally, the gut microbiome and its role in ICC is beginning to emerge. Fecal samples from ICC patients exhibited unique gut microbiota composition with greater diversity when compared to healthy-matched controls [22,23]. Gut dysbiosis has been associated with tumorigenesis through inflammation and cytokine modulation, but its role in HPV clearance and cervical carcinogenesis is still unclear [5]. Our group’s ongoing studies suggest that both the cervical and gut microbiome are associated with treatment response in cervical cancers [24].
16S rRNA studies assessing the cervicovaginal microbiome account for the majority of ICC studies. ICC patients exhibit decreases in abundance of Lactobacillus spp., increases in overall bacterial diversity and richness, and an increased predominance of Fusobacterium spp. As with CIN, the ICC microbial profile resembles that of BV.
The transition of CIN to invasive disease does not seem to result in major vaginal microbiome shifts, as similar states of dysbiosis facilitate the persistence and progression of HPV-driven disease. Although observed in both cervical disease states, Fusobacterium predominance was more commonly observed in ICC patients.
Fusobacterium was found to be associated with increased levels of IL-4 and transforming growth factor (TGF)-β1 mRNA, suggesting a role in immunosuppression within the ICC microenvironment [12]. Overall, 16S rRNA analysis demonstrates similar shifts within the ICC and CIN microbiome profiles that likely begin with the disappearance of Lactobacillus spp. This decline in the predominating protective bacteria results in increased vaginal pH levels, weakened pathogenic defenses, and damaged mucosal barriers [14,17,25].
Eventually, these conditions allow for opportunistic anaerobic and microaerophilic bacteria to thrive driving the diversity of the cervical microbiome to a state of dysbiosis. Foreign bacteria cause disrupted immune responses and elevated inflammation levels [20]. Together, these factors contribute to an optimal environment for HPV carcinogenesis.
Microbiome factors in other HPV-driven cancers
Despite numerous studies assessing the microbiome in oral cavity cancers (OCCs) and OPCs, most of these studies do not specify HPV positivity or instead focus on non-HPV–related oral cancers. The section labeled HNSCC (Head Neck Squamous Cell Carcinoma) in Table 1 presents the studies focusing on HPV-positive oral cancers and OPCs. In unknown HPV-status OCCs, bacteria colonizing the tumor site were determined to be significantly different than matching contralateral normal mucosa samples [26].
Furthermore, sensitive microbial variations at intraoral sites like the tooth surface, gums, and tongue exist [27]. These findings suggest the importance of site sampling and sampling collection methods when comparing oral microbiome analyses. When considering HPV positivity, HPV-positive OCC and OPC patients exhibit distinct oral microbiome profiles from both healthy controls and HPV-negative OCC and OPC patients, suggesting the presence of HPV influences the composition of the oral microbiome [26,28].
HPV-positive OCC and OPC patients both showed an abundance of Gemella and Leuconostoc, while Haemophilus correlated with HPV infection [26,28]. 16S rRNA sequencing on saliva and oral rinse samples of OCC and OPC patients revealed a decrease in richness and diversity when compared to control patients [26,28]. This decrease in diversity is opposite to cervical patients and suggests that a few dominating, pathogenic bacteria may be influencing HPV persistence and carcinogenesis in the oral environment.
Interestingly, Lactobacillus spp. were found to be significantly associated with HPV-positive OPC patient saliva samples [26,29]. In a follow-up study, species-level context was provided for the Lactobacillus spp. using high-resolution 16S rRNA analysis. A subset of OPC patient samples were enriched with commensal species from the vaginal flora, including L. gasseri/johnsonii and L. vaginalis, not seen in control groups nor saliva from the Human Microbiome Project [29].
The discovery of Lactobacillus in the oral microbiome of these samples is not well understood, as Lactobacillus is often protective in vaginal and oral contexts [29]. It was suggested that these normally commensal vaginal species could have been transferred to the oral flora during oral sex, which, if validated, would have interesting implications in the role of vaginal-associated Lactobacillus during oral HPV disease.
Beyond cervical cancers and OPCs, research characterizing the microbiome of other HPV-driven cancers is relatively nonexistent. Characterization of the anal cancer microbiome would be particularly interesting because of direct interactions with the gut microbiota, but studies have yet to be published, likely because of disease rarity.
reference link:https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1008524
